Avantor, Inc. 10-Q Summary: Q2 2026
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2026. Avantor, Inc. operates as a global manufacturer and distributor serving the biopharmaceutical, healthcare, education, government, and advanced technology sectors. Effective January 1, 2026, the company revised its reporting structure to two operating segments: Bioscience & Medtech Products and VWR Distribution & Services.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Net Sales | $1,692.3M | $1,683.4M | $3,273.7M | $3,264.8M |
| Gross Margin | 31.7% | 32.9% | 31.7% | 33.4% |
| Operating Income | $121.8M | $128.8M | $221.3M | $276.2M |
| Net Income | $38.1M | $64.7M | $81.4M | $129.2M |
| Diluted EPS | $0.06 | $0.09 | $0.12 | $0.19 |
| Adjusted EBITDA | $254.3M | $279.8M | $473.7M | $549.3M |
| Cash from Operations (YTD) | $236.9M | $263.7M | - | - |
| Free Cash Flow (YTD) | $168.0M | $207.5M | - | - |
| Total Debt (Gross) | $3,715.4M | $3,967.9M | - | - |
| Cash & Equivalents | $306.8M | $365.4M | - | - |
Material Changes vs. Prior Period
- Revenue: Net sales increased 0.5% QoQ and 0.3% YTD, driven by favorable foreign currency impacts ($15.7M in Q2; $80.0M YTD). However, organic net sales declined 0.4% in Q2 and 2.2% YTD due to lower volumes in Fluid Handling, NuSil, and lab consumables.
- Profitability: Gross margin contracted 120 basis points in Q2 and 170 basis points YTD due to unfavorable product mix, inflationary pressures, and higher inventory reserves. Operating income decreased 5.4% in Q2 and 20.0% YTD.
- Tax Rate: The effective tax rate increased significantly to 53.1% in Q2 (vs. 20.8% prior year) and 40.5% YTD (vs. 22.8% prior year), primarily due to changes in estimates for uncertain tax positions.
- Debt Reduction: The company prepaid $102.5M on Euro term loans in Q2, reducing total gross debt by approximately $252.5M compared to year-end 2025.
Outlook, Risks, and Management Commentary
- Goodwill Impairment Risk: Management highlighted a significant risk regarding the VWR Distribution reporting unit. In Q1 2026, a decline in share price triggered an interim impairment test. While no impairment was recorded, the fair value exceeded the carrying value by only ~5.5%. Management warns that further deterioration in market conditions or operating performance could trigger a material non-cash goodwill impairment charge in the future.
- Segment Performance: The Bioscience & Medtech Products segment saw organic sales declines driven by Fluid Handling and NuSil. The VWR Distribution & Services segment saw organic growth in controlled environment consumables but declines in lab consumables.
- Legal Proceedings: The company is defending against consolidated securities class action lawsuits filed in late 2025 alleging misleading statements regarding competitive position and goodwill. Management disputes the claims and does not believe a loss is probable at this time.
- Future Tax Benefit: A post-balance sheet internal reorganization is expected to generate a deferred tax benefit of approximately $142.0 million, to be recognized in a subsequent period.
Investor Verification Checklist
- Goodwill Sensitivity: Verify the assumptions used in the Q1 2026 goodwill impairment test for the VWR Distribution unit, specifically the discount rates and cash flow projections, given the narrow margin of safety.
- Organic Sales Trends: Monitor the trajectory of organic sales declines in the Fluid Handling and NuSil businesses to assess if volume losses are structural or cyclical.
- Tax Provision: Review the details of the "change in estimate of uncertain tax positions" that drove the effective tax rate to 53.1% in Q2.
- Debt Covenants: Confirm continued compliance with leverage and interest coverage covenants, especially given the recent debt prepayments and potential future impairment charges.
- Legal Exposure: Track the status of the securities class action litigation and any potential settlement discussions.